These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

496 related items for PubMed ID: 31404822

  • 21. Cardiovascular event reduction with PCSK9 inhibition among 1578 patients with familial hypercholesterolemia: Results from the SPIRE randomized trials of bococizumab.
    Ridker PM, Rose LM, Kastelein JJP, Santos RD, Wei C, Revkin J, Yunis C, Tardif JC, Shear CL, Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Investigators.
    J Clin Lipidol; 2018; 12(4):958-965. PubMed ID: 29685591
    [Abstract] [Full Text] [Related]

  • 22. What Proportion of Patients Admitted with Stroke or Transient Ischemic Attack May Be Suitable for Newer Cholesterol-Lowering Treatment?
    Alakbarzade V, Pereira AC.
    J Stroke Cerebrovasc Dis; 2020 Jan; 29(1):104457. PubMed ID: 31732461
    [Abstract] [Full Text] [Related]

  • 23. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA, Handelsman Y, Koren M.
    Vasc Health Risk Manag; 2020 Jan; 16():403-418. PubMed ID: 33116551
    [Abstract] [Full Text] [Related]

  • 24. PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety.
    Roth EM, Davidson MH.
    Rev Cardiovasc Med; 2018 Jan; 19(S1):S31-S46. PubMed ID: 30207556
    [Abstract] [Full Text] [Related]

  • 25. Lipid management in ACS: Should we go lower faster?
    Gencer B, Mach F.
    Atherosclerosis; 2018 Aug; 275():368-375. PubMed ID: 30015301
    [Abstract] [Full Text] [Related]

  • 26. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
    Hadjiphilippou S, Ray KK.
    Heart; 2017 Nov; 103(21):1670-1679. PubMed ID: 28596304
    [Abstract] [Full Text] [Related]

  • 27. Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels - experimental and clinical approaches with lipid-lowering agents.
    Macchi C, Banach M, Corsini A, Sirtori CR, Ferri N, Ruscica M.
    Eur J Prev Cardiol; 2019 Jun; 26(9):930-949. PubMed ID: 30776916
    [Abstract] [Full Text] [Related]

  • 28. Statins and PCSK9 inhibitors: A new lipid-lowering therapy.
    Gallego-Colon E, Daum A, Yosefy C.
    Eur J Pharmacol; 2020 Jul 05; 878():173114. PubMed ID: 32302598
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?
    Noto D, Giammanco A, Barbagallo CM, Cefalù AB, Averna MR.
    Cardiovasc Res; 2018 Oct 01; 114(12):1595-1604. PubMed ID: 29931148
    [Abstract] [Full Text] [Related]

  • 31. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ, Wohlford GF, Pozen J.
    Curr Atheroscler Rep; 2019 Mar 16; 21(5):16. PubMed ID: 30877491
    [Abstract] [Full Text] [Related]

  • 32. The Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition on Sterol Absorption Markers in a Cohort of Real-World Patients.
    Brandt EJ, Benes LB, Lee L, Dayspring TD, Sorrentino M, Davidson M.
    J Cardiovasc Pharmacol Ther; 2019 Jan 16; 24(1):54-61. PubMed ID: 29940784
    [Abstract] [Full Text] [Related]

  • 33. Proprotein convertase subtilisin/kexin type 9 inhibitors: New insights into cardiovascular atherosclerotic pathophysiology with therapeutic implications.
    Cokkinos DV, Cokkinos P, Kolovou G.
    Arch Cardiovasc Dis; 2019 Jan 16; 112(8-9):455-458. PubMed ID: 31495741
    [No Abstract] [Full Text] [Related]

  • 34. Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study.
    Hollstein T, Vogt A, Grenkowitz T, Stojakovic T, März W, Laufs U, Bölükbasi B, Steinhagen-Thiessen E, Scharnagl H, Kassner U.
    Vascul Pharmacol; 2019 May 16; 116():8-15. PubMed ID: 30910670
    [Abstract] [Full Text] [Related]

  • 35. The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
    Marston NA, Gurmu Y, Melloni GEM, Bonaca M, Gencer B, Sever PS, Pedersen TR, Keech AC, Roselli C, Lubitz SA, Ellinor PT, O'Donoghue ML, Giugliano RP, Ruff CT, Sabatine MS.
    Circulation; 2020 May 19; 141(20):1600-1607. PubMed ID: 32223429
    [Abstract] [Full Text] [Related]

  • 36. PCSK9 Biology and Its Role in Atherothrombosis.
    Barale C, Melchionda E, Morotti A, Russo I.
    Int J Mol Sci; 2021 May 30; 22(11):. PubMed ID: 34070931
    [Abstract] [Full Text] [Related]

  • 37. Identifying Patients for Nonstatin Therapy.
    Robinson JG, Watson KE.
    Rev Cardiovasc Med; 2018 May 30; 19(S1):S1-S8. PubMed ID: 30207552
    [Abstract] [Full Text] [Related]

  • 38. LDL cholesterol: How low to go?
    Packard CJ.
    Trends Cardiovasc Med; 2018 Jul 30; 28(5):348-354. PubMed ID: 29336946
    [Abstract] [Full Text] [Related]

  • 39. The PCSK9 revolution: Current status, controversies, and future directions.
    Warden BA, Fazio S, Shapiro MD.
    Trends Cardiovasc Med; 2020 Apr 30; 30(3):179-185. PubMed ID: 31151804
    [Abstract] [Full Text] [Related]

  • 40. Lipid-lowering therapy with PCSK9-inhibitors in the real-world setting: Two-year experience of a regional lipid clinic.
    Zafrir B, Jubran A.
    Cardiovasc Ther; 2018 Oct 30; 36(5):e12439. PubMed ID: 29863817
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.